Johnson & Johnson has joined AbbVie as a partner for Morphic Therapeutic and its small-molecule integrin platform, pledging up to $725 million to the cause.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,